Supplementary Data-clean from Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Table S1: Efficacy by investigator assessment. Supplementary Table S2: Objective response rate by Central Radiographic Assessment in key subgroups of interest. Supplementary Table S3: Efficacy in 3L patients by Central Radiographic Assessment. Supplementary Table S4: Deaths attributable to drug-related, treatment-emergent adverse events (TEAEs). Supplementary Table S5. Overview of pleural effusions. Supplementary Table S6. Overview of pericardial effusions. Supplementary Table S7. Overview of edema. Supplementary Table S8: Overview of cutaneous reactions.
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361934614